Nevro has a 12-month low of $3.17 and a 12-month high of $13.30. The firm has a market cap of $224.32 million, a P/E ratio of -3.09 and a beta of 0.81.

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City, California ...

Nevro's full-year 2024 worldwide revenue was $408.5 million, a decrease of 3.9% as reported and 4.0% on a constant currency basis, compared with $425.2 million for full-year 2023.

Nevro has a 1-year low of $3.16 and a 1-year high of $17.63. Institutional Trading of Nevro Hedge funds have recently made changes to their positions in the business.

Globus Medical plans to buy spinal cord stimulation company Nevro for about $250 million, the companies announced on Thursday. Globus will pay $5.85 per share in an all-cash purchase, a 27% premium to ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on December 7, 2024, the ...

A Closer Look at Nevro’s Stock Performance Nevro’s stock has faced some significant headwinds this year, with its YTD performance showing a sharp decline of -75.28%. This is quite a contrast to the ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Monday reported a loss of $15.3 million in its third quarter. The Redwood City, California-based company said it ...